|
Caballero L, Climent V, Hernández-Romero D, Quintanilla MA, de la Morena G, Marín F. Enzyme replacement therapy in Fabry disease: influence on cardiac manifestations. Curr Med Chem. 2010;17(16):1679-89. Review. PubMed PMID: 20345350.
AÑO: 2010; IF: 4.63
|
20345350
|
Cambronero F, Marín F, Roldán V, Hernández-Romero D, Valdés M, Lip GY. Biomarkers of pathophysiology in hypertrophic cardiomyopathy: implications for clinical management and prognosis. Eur Heart J. 2009 Jan;30(2):139-51. doi: 10.1093/eurheartj/ehn538. Epub 2009 Jan 9. Review. PubMed PMID: 19136482.
AÑO: 2009; IF: 9.8
|
|
Saura D, Marín F, Climent V, González J, Roldán V, Hernández-Romero D, Oliva MJ, Sabater M, de la Morena G, Lip GY, Valdés M. Left atrial remodelling in hypertrophic cardiomyopathy: relation with exercise capacity and biochemical markers of tissue strain and remodelling. Int J Clin Pract. 2009 Oct;63(10):1465-71. doi: 10.1111/j.1742-1241.2009.02127.x. PubMed PMID: 19769703.
AÑO: 2009; IF: 2.245
|
|
Pérez-Andreu V, Roldán V, González-Conejero R, Hernández-Romero D, Vicente V, Marín F. Implications of pharmacogenetics for oral anticoagulants metabolism. Curr Drug Metab. 2009 Jul;10(6):632-42. PubMed PMID: 19799531.
AÑO: 2009; IF: 3.989
|
|
Alcaraz A, Hernández D, Iyú D, Mota R, Atucha NM, Ortiz AJ, García-Estañ J, Ortiz MC. Effects of chronic L-NAME on nitrotyrosine expression and renal vascular reactivity in rats with chronic bile-duct ligation. Clin Sci (Lond). 2008 Jul;115(2):57-68. doi: 10.1042/CS20070312. PubMed PMID: 18184108.
AÑO: 2008; IF: 4.187
|